Pfizer recently announced positive results from the BASIS study, the global phase 3 trial evaluating Hympavzi in young adults ...

Results from the Phase III BASIS trial show that once-weekly subcutaneous Hympavzi reduced annualized bleeding rates by 93% compared to on-demand treatment with bypassing agents in patients with ...

Pfizer Inc. (NYSE:PFE) ranks among the best set-it-and-forget-it stocks to buy. On June 26, Pfizer Inc. (NYSE:PFE) declared ...

Pfizer Inc. (PFE) on Thursday said that its therapy Hympavzi demonstrated improvement in bleeding outcomes for adults and adolescents living with hemophilia A or B with inhibitors in a late-stage ...

Approved eight months ago for a certain class of patients with both hemophilia A or B, Pfizer’s Hympavzi has now shown its effectiveness in another group of patients with the bleeding disorder. | ...

On June 26, Pfizer announced positive topline results from its Phase 3 BASIS study evaluating HYMPAVZI (marstacimab) for ...

Pfizer Inc. (NYSE: PFE)today announced positive topline results from the Phase 3 BASIS study (NCT03938792) evaluating HYMPAVZI™ (marstacimab) for adults and adolescents living with hemophilia A ...

US pharm giant Pfizer today announced positive top-line results from the Phase III BASIS study evaluating Hympavzi (marstacimab) for adults and adolescents living with hemophilia A or B with ...

Pfizer said a late-stage study of its Hympavzi hemophilia drug met its key goals in patients with the blood-clotting disorder who have inhibitors that can render some treatments ineffective.

Pfizer's Hympavzi showed superior bleed control in hemophilia A and B patients with inhibitors, reducing bleeding rates and showing good tolerability.

Pfizer's hemophilia therapy, Hympavzi, met the main goal of a late-stage study in patients with certain types of antibodies, the U.S. drugmaker said on Thursday.